632
Participants
Start Date
November 30, 2007
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
MCI-196
3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
Another Phosphate binder (Sevelamer)
Current approved dosing recommendations for 12 weeks
Graz
Frýdek-Místek
Hradec Králové
Ostrava
Prague
Tábor
Ústí nad Labem
Bordeaux
Montpelier
Paris
Aschaffenburg
Coesfeld
Darmstadt
Dortmund
Düsseldorf
Hamburg
Homberg (Efze)
Langen
Mannheim-Kafertal
Ajka
Baja
Budapest
Esztergom
Győr
Hatvan
Kisvárda
Veszprém
Ancona
Cernusco sul Naviglio
Como
Cremona
Lecco
Livorno
Milan
Modena
Ostia Roma
Pavia
Perugia
Rome
Alor Star
Klang
Kota Kinabalu
Kuala Terengganu
Kuching
Malacca
Selangor Darul Ehsan
Seremban
Taiping
Skopje
Ciechanów
Częstochowa
Gdansk
Lodz
Lublin
Oświęcim
Pabianice
Poznan
Rybnik
Sokołów Podlaski
Starogard Gdański
Warsaw
Wejherowo
Wroclaw
Zgierz
Zielona Góra
Arkhangelsk
Chita
Irkutsk
Ivanovo
Kaluga
Karbysheva str.Volzskiy
Kemerovo
Khabarovsk
Krasnodar
Krasnoyarsk
Moscow
Mytishchi
Nizhny Novgorod
Novokuznetsk
Novorossiysk
Novosibirsk
Omsk
Petrozavodsk
Rostov-on-Don
Rozhkova
Saint Petersburg
Smolensk
Tomsk
Vladivostok
Yaroslavl
Yekaterinburg
Belgrade
Kragujevac
Niš
Novi Sad
Cape Town
Durban
Gauteng
Johannesburg
Port Elizabeth
Barcelona
Oviedo
Seville
Chernivtsy
Dnipro
Ivano-Frankivsk
Kharkiv
Kiev
Mykolayiv
Ternopil
Uzhhorod
Zaporizhya
Zhytomyr
Glasgow
Stevenage
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
INDUSTRY